CLASS III Device recall · Reported 7 Nov 2012 · FDA Enforcement Report

cobas 4800 BRAF V600 Mutation Test recalled by Roche Molecular Systems

Roche Molecular Systems is recalling cobas 4800 BRAF V600 Mutation Test for In Vitro Diagnostic Use Roche Molecular Systems. The recall was initiated on 31 Jul 2012 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesMaterial number 05985595190; Lot number R03607
Quantity recalled44 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0188-2013
FDA event ID
63310
Recalling firm
Roche Molecular Systems, Branchburg, NJ
Classification
Class III
Status
Terminated
Recall initiated
31 Jul 2012
FDA classified
1 Nov 2012
Reported
7 Nov 2012
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Packaging Defects

Timeline

31 Jul 2012Recall initiated by company
1 Nov 2012Classified by FDA+93 days
7 Nov 2012Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

It was identified that BRAF controls dispositioned as "Internal Use Only" were incorrectly packaged into cobas 4800 BRAF V600 Mutation Test CE-IVD kit lot R03607 and released for distribution. Two control batches manufactured during two process validation studies are involved: PV7711: BRAF Mutant (MUT) Control PV0853: BRAF Wild Type (WT) Control

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

cobas 4800 BRAF V600 Mutation Test for In Vitro Diagnostic Use Roche Molecular Systems, Inc., Product Usage: The primary use of the cobas 4800 BRAF V600 Mutation Test is the detection of the BRAF V600 mutations in DNA extracted from formalin-fixed, paraffin-embedded human melanoma tissue. It is intended to be used as an aid in selecting melanoma patients whose tumors carry BRAF V600 mutations for treatment with Zelboraf (vemurafenib).

Where it was distributed

Worldwide Distribution - Australia, Austria, Belgium, China, Hungary, Turkey and United Kingdom.

Questions about this recall

Is cobas 4800 BRAF V600 Mutation Test for In Vitro Diagnostic Use Roche Molecular Systems recalled?

Yes. Roche Molecular Systems recalled cobas 4800 BRAF V600 Mutation Test for In Vitro Diagnostic Use Roche Molecular Systems on 31 Jul 2012. The recall is Class III and its status is Terminated. Recall number Z-0188-2013.

Why was it recalled?

It was identified that BRAF controls dispositioned as "Internal Use Only" were incorrectly packaged into cobas 4800 BRAF V600 Mutation Test CE-IVD kit lot R03607 and released for distribution. Two control batches manufactured during two process validation studies are involved: PV7711: BRAF Mutant (MUT) Control PV0853: BRAF Wild Type (WT) Control

Which lots are affected?

Material number 05985595190; Lot number R03607

Where was it sold?

Worldwide Distribution - Australia, Austria, Belgium, China, Hungary, Turkey and United Kingdom.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Roche Molecular Systems

All 42

Other Test Kits & Diagnostics recalls

All 2,656